Pharm Exec Podcast
1) Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 billion licensing agreement with Jacobio Pharma for a...Show More
2) Scaling Sustainability: A Big Pharma Formula
In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (ESG) goals are shaping the organization's next pha...Show More
3) Pharmaceutical Executive Daily: US Senate Passes Biosecure Act
In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for...Show More
4) Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collabora...Show More
5) Pharmaceutical Executive Daily: FDA's Approval of Lerochol
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s disease and B-cell depletion, and the agency issues a ...Show More
6) Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot
In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi annou...Show More
7) Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...Show More
8) Pharmaceutical Executive Daily: FDA's Approval of Waskyra
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR The...Show More
9) Pharmaceutical Executive Daily: FDA's New Standard for CAR-T Approvals
In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novartis form a $1 billion multi-program collaboration ta...Show More
10) Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions
In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data show sustained remissions with Carvykti in relapsed ...Show More